LLY vs REGN
By Alex · Tickerpine
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | REGN |
|---|---|---|
| Price | $1,208.12 | $632.90 |
| Market cap | $1.08T | $66.35B |
| P/E ratio | 42.9 | 15.5 |
| ROE | 107.46% | 14.55% |
| Profit margin | 34.99% | 29.65% |
| Revenue growth | 55.50% | 19.00% |
| Dividend yield | 0.57% | 0.59% |
| Beta | 0.52 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs REGN in plain English
- LLY is the bigger company — about 16.2× the market cap of REGN.
- REGN is cheaper on earnings (P/E 15.5 vs 42.9).
- LLY earns a higher return on equity (107% vs 15%).
- LLY is growing revenue faster (56% vs 19%).
- REGN has the higher dividend yield (0.59% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.